Long-Acting Reversible Contraceptives Await “Obamacare” Boost
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Contraception coverage mandated by the Affordable Care Act could unlock demand for IUDs. Actavis aims to provide an alternative to Bayer’s hormone-eluting IUD in 2014; public sector rights to Levosert are assigned to nonprofit Medicines360.